Your session is about to expire
← Back to Search
Brentuximab Vedotin + Nivolumab for Hodgkin's Lymphoma
Study Summary
This trial compares adding immunotherapy to standard chemo/radiation for Hodgkin lymphoma to improve survival.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a weak immune system that is not well-managed.I am 17 or younger with a moderate ability to carry out daily activities.I am between 5 and 60 years old.I have a tumor that is at least 1.5 cm large.I haven't taken steroids or immunosuppressants in the last 14 days.I have received chemotherapy, radiation, or antibody treatment for Hodgkin lymphoma.I have had a solid organ or stem cell transplant.My kidneys work well enough (creatinine clearance >= 30 mL/min).I have been newly diagnosed with early-stage classic Hodgkin lymphoma.I do not have other cancers that could affect this treatment's safety or results.I have nodular lymphocyte predominant Hodgkin lymphoma.I have not received a live vaccine in the last 30 days.I am a child (5-17) with a chest X-ray or an adult with a chest X-ray/CT scan.I am 18 or older and can take care of myself, with varying levels of assistance.I am HIV-positive, on treatment, and my viral load is undetectable.I have had active lung inflammation or disease in the past.I had a PET scan within the last 42 days.My lung function test shows I can breathe well enough.My child's kidney function tests are within the required range for their age and gender.My hepatitis B is under control with treatment, or I was treated and cured of hepatitis C.I do not have severe nerve damage or Charcot-Marie-Tooth disease.I am sexually active and not using effective birth control.
- Group 1: Arm G (ABVD, eBEACOPP, ISRT)
- Group 2: Arm A (ABVD)
- Group 3: Arm B (ABVD, brentuximab vedotin, nivolumab)
- Group 4: Arm C (ABVD, eBEACOPP, ISRT)
- Group 5: Arm D (ABVD, brentuximab vedotin, nivolumab, ISRT)
- Group 6: Arm E (ABVD, AVD)
- Group 7: Arm F (ABVD, brentuximab vedotin, nivolumab)
- Group 8: Arm H (ABVD, brentuximab vedotin, nivolumab, ISRT)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In what quantity of locations is this examination being conducted?
"The trial is currently running out of Ochsner Medical Center Jefferson in New Orleans, Louisiana, Roswell Park Cancer Institute in Buffalo, New york and NYU Winthrop Hospital in Mineola Rhode island amongst 7 other medical centres."
How many participants are there in this trial?
"This medical study necessitates the participation of 1875 people who fit its criteria. Potential participants can come from two of our major sites, namely Ochsner Medical Center Jefferson in New Orleans and Roswell Park Cancer Institute in Buffalo."
Do the age limitations for this research project preclude those over 69 years of age?
"This study seeks to recruit participants aged 5 and 60. There are 311 trials available for minors, while seniors have access to 1547 clinical studies."
Is participation in this clinical research still feasible for individuals?
"Affirmative, clinicaltrials.gov states that this study remains open for participants to enroll in. It was inaugurated on April 28th of 2023 and its information has been recently updated on May 12th of the same year. 1,875 people can apply at seven different sites."
Who meets the criteria for participating in this research endeavor?
"Eligibility for this trial requires individuals to be between the ages of 5 and 60, with a diagnosis of Hodgkin's lymphoma. At present, approximately 1875 patients are being recruited."
Is there an inherent danger to utilizing the Arm B (ABVD, brentuximab vedotin, nivolumab) regimen?
"Our team at Power gave Arm B (ABVD, brentuximab vedotin, nivolumab) a score of 3 due to the multiple trials that provided evidence for its efficacy and safety."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger